Orion Corporation

Carola Tilgmann

Piero Pollesello

Heimo O Haikala

Jouko Levijoki

Juha Kaivola

Jukka Tenhunen

Martti Ovaska

Timo Lotta

Jukka Vidgren

Marjo Yliperttula-Ikonen

Arto J Karjalainen

Jarmo J Pystynen

Pentti T Nore

Eija Tiainen

Seppo Parhi

Petri Kaheinen

Kari L&ouml;nnberg

Ismo Ulmanen

A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.

Method for the prevention of thromboembolic disorders

This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, physicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of the active site of phospholamban.

Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors)

This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, phsicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of phospholamban.

Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)

A method for obtaining direct dilatation of the coronary arteries by administering a therapeutically effective amount of a phospholamban inhibitor is described. Compounds which are effective in relieving the inhibitory effects of phospholamban on cardiac sarcoplasmic reticulum Ca,-ATPase are also described.

Phospholamban inhibitors and a method for increasing coronary flow

Growing community of inventors

Jorvas, Finland

Carola Tilgmann